Medscape: Estrogen Agonists/Antagonists in Combination With Estrogen for Prevention and Treatment of Menopause-associated Signs and Symptoms
Estrogen agonists/antagonists are compounds with tissue-selective actions. The pharmacological goal of these compounds is to produce beneficial estrogenic actions in certain tissues (e.g., bone and ...
Estrogen Agonists/Antagonists in Combination With Estrogen for Prevention and Treatment of Menopause-associated Signs and Symptoms
Addressing overdoses from “street drugs” containing potent synthetic opioids poses a key challenge when utilizing opioid antagonists. A standard approach to known or suspected opioid overdose includes ...
Renal & Urology News: GnRH Antagonist vs Agonist for Metastatic Prostate Cancer Tied With Lower Mortality
Use of a gonadotropin-releasing hormone antagonist is associated with lower risks for death than GnRH agonists, a systematic review and meta-analysis found. Use of degarelix, a gonadotropin-releasing ...
GnRH Antagonist vs Agonist for Metastatic Prostate Cancer Tied With Lower Mortality
Monthly Prescribing Reference: GnRH Antagonists vs LHRH Agonists Tied With Higher MACE Risk
On the big screen, the antagonist typically plays a devious role. His or her goal is to undermine the lead character, creating drama and conflict. But in the weight room, it's a different story. Every ...
ascopubs.org: Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone ...
Quality of life differences for LHRH-antagonist versus LHRH-agonist in special patient groups with cardiovascular comorbidities and higher tumor burden in patients with hormone ...
ascopubs.org: Randomized controlled trial of GnRH antagonist monotherapy versus GnRH agonist plus bicalutamide (CAB) for patients with metastatic hormone-sensitive prostate cancer (mHSPC ...
Randomized controlled trial of GnRH antagonist monotherapy versus GnRH agonist plus bicalutamide (CAB) for patients with metastatic hormone-sensitive prostate cancer (mHSPC ...